Attometrics

Attometrics is a biotechnology company based in an undisclosed location that develops diagnostic technology designed to detect proteins, metabolites, and DNA for medical diagnostics and life sciences research. The organization focuses on the cancer diagnostics market by building systems that identify biological markers, including a metabolomics liquid biopsy platform utilizing machine learning to detect early lung, glioblastoma, breast, and neuroendocrine tumors. This technology measures specific metabolites, such as N-acetylamantadine derived from the SSAT enzyme, to enable noninvasive urine detection, treatment response monitoring, and disease recurrence tracking. Operating with a portfolio of over 25 issued or pending patents, the company generated diagnostic results in 2018 through a collaboration with the Alberta Machine Learning Institute. Following these developments, the enterprise targeted commercialization for the fourth quarter of 2023, while its specific founding year and original founders remain undisclosed.